Navigation Links
Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
Date:7/9/2008

XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease

Patients in Real-World Setting

ABBOTT PARK, Ill., July 9 /PRNewswire-FirstCall/ -- Abbott today announced the start of the XIENCE V(TM) USA post-approval study, with six hospital centers already recruiting and enrolling patients just one week after the U.S. Food and Drug Administration approved the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The XIENCE V USA study will evaluate the safety and effectiveness of the XIENCE V drug eluting stent in a real-world clinical setting out to five years. Jack Jones, M.D., interventional cardiologist and medical director of the Stormont-Vail Catheterization Lab in Topeka, Kan., was one of the first physicians to enroll a patient into the study.

"XIENCE V is an important innovation that gives patients in the United States access to a next-generation drug eluting stent that has been shown in clinical trials to improve patient outcomes," said Dr. Jones. "During the stent procedure, we found it easy to deliver XIENCE V to the diseased portion of the vessel. With its combination of clinical efficacy and deliverability, I believe that XIENCE V will become a key advancement in the treatment of coronary artery disease."

The XIENCE V USA study is designed to evaluate at least 5,000 coronary artery disease patients treated with the XIENCE V drug eluting stent at approximately 250 centers across the United States. The primary endpoint of XIENCE V USA is a measure of stent thrombosis (formation of blood clots) every year out to five years, as defined by the Dublin/Academic Research Consortium (ARC). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

The co-primary endpoint of the study is the composite rate of cardiac death and any heart attack (Q-wave or non-Q-wave myocardial infarction) in patients at one year.
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 2009 , , ARVADA, Colo., June 16 ... and responsibility to our shareholders, is addressing our recent ... Finance 2009, a Biotechnology, Medical Devices, and world public ... 4-5. , , Pharma Finance is an international ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a ... oncology therapeutics for the treatment of solid and hematologic cancers, ... will be presenting at the Jefferies 3rd Annual Healthcare Conference ... 17, 2009. , , The live webcast of this ...
... SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a,Shanghai-based ... facility in Shanghai has passed the audit from a ... are praised,for providing good facilities and programs for the ... The inspection and audit took place in May. ...
Cached Biology Technology:GeneThera Extends its Reach Overseas 2Sundia's Animal Facility Passed Client and Government Inspection 2
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (UK) are to investigate how lethal viruses attack differently sized ... the door to new methods of pest control. The project, ... grain-infesting Indian meal moth ( Plodia interpunctella ) and a ... and sometimes not. Dr Steve Sait from the University ...
... Virginia Tech released today the results of a new rating ... the risk of concussions. One currently manufactured helmet received ... helmets received the very good "4-star" rating. ... first time researchers have provided the public with comparative test ...
... Palo Alto, CA Accurately calculating the amount of ... bringing products to our doorsteps is nearly impossible, but ... a commentary published online this week by Proceedings of ... Ken Caldeira and Steven Davis commend the work of ...
Cached Biology News:No safety in numbers for moths and butterflies 2Virginia Tech announces football helmet ratings for reducing concussion risk 2Virginia Tech announces football helmet ratings for reducing concussion risk 3Virginia Tech announces football helmet ratings for reducing concussion risk 4Consumption, carbon emissions and international trade 2
... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
Human Cell Line Slides...
Request Info...
HSV 1 IgM...
Biology Products: